image: Lluís Camprubí Ferrer
Credit: Ingemar Hultquist, Lund University
Researchers at Lund University in Sweden have identified a key role for the protein galectin-3 in Alzheimer's disease. The study shows that galectin-3 not only influences how the brain's immune cells, known as microglia, react to the disease's characteristic amyloid plaques.The protein also shapes the plaques themselves — and may contribute to the nerve damage that develops around them.
Type of research: Basic research // Methods of research: Animal study // Applied research // Data/statistical analysis // Experimental study // Imaging analysis // Quantitative study // Subject of research: Animal tissue samples (mice) // Cells // Human tissue samples // Experimental investigation: Ex vivo // In vitro // In vivo
"This discovery provides new insights into the mechanisms of the disease and identifies galectin-3 as a potential future therapeutic target", says Lluís Camprubí-Ferrer, one of the study's lead authors and a postdoctoral researcher at Lund University.
Alzheimer's disease (AD) is characterised by accumulations of beta-amyloid (Aβ) in the brain. These proteins clump together to form plaques. In a previous study (see link below), the research team at Lund University showed for the first time that the protein galectin-3 increases in the brains of people with Alzheimer's disease, and that removing the protein decreased inflammation in the brain. In this new study, the researchers have shown the direct relationship between galectin-3 and Aβ plaques.
The results of the animal studies are clear-cut, showing a cause-and-effect relationship. The experiments on human tissue, from nine individuals, show a strong correlation.
The new study shows that galectin-3 binds "with remarkable strength" to Aβ, and that it acts in two places at once. Outside the microglia it sits on the plaque itself, where it changes the shape of the amyloid fibres as they grow. Inside the microglia it sits in the lysosomes (the compartments where the cell breaks down what it has swallowed) where it steers how amyloid is processed. Galectin-3, the researchers conclude, is not merely present around the plaque: it actively shapes it.
"No one has previously shown what galectin-3 does to the plaque itself. We have observed that the protein binds to long protein strands known as amyloid fibrils, blocking one of the steps by which they multiply and altering their shape. In cell experiments, the fibrils reshaped by galectin-3 went on to damage nerve cells", explains Lluís Camprubí-Ferrer.
The current study was carried out on both mice and human tissue, in collaboration with the University of Seville and the Instituto de Biomedicina de Sevilla (IBiS), in Spain. When the researchers removed galectin-3 in mice with an Alzheimer's-like disease, the plaques became smaller and more tightly packed. The surrounding nerve endings were damaged to a significantly lesser extent, and the immune cells (microglia) shifted from an aggressive, inflammatory state to a protective one.
"When we inactivated galectin-3, microglia transitioned from their harmful state to a state rich in the protective receptor TREM2, a protein that we know plays an important role in the brain's immune defence and in the risk of Alzheimer's disease", says Lluís Camprubí-Ferrer.
The results of the animal studies are clear-cut, showing a cause-and-effect relationship. The experiments on human tissue, from nine individuals, show a strong correlation. What the researchers cannot yet say is whether blocking galectin-3 helps patients. Only a clinical trial can provide an answer to that.
"This is important because current Alzheimer's drugs target amyloid without helping to reduce inflammation in the brain. And galectin-3 is a protein that drugs can actually bind to", says Lluís Camprubí-Ferrer.
"And the timing is right. Drugs containing antibodies that break down amyloid have reached patients, but their modest effect has drawn attention to the brain's immune response. That is where we can now fill in the gaps", says Tomas Deierborg, professor and leader of the Experimental Neuroinflammation research group at Lund University.
Tomas Deierborg finds it particularly encouraging that their early discoveries have now led to clinical trials. Just a few weeks ago, US regulators gave the go-ahead for a Phase 2 trial of an antibody that blocks galectin-3.
"This demonstrates the clinical potential of our research findings", says Tomas Deierborg.
Journal
Proceedings of the National Academy of Sciences
Method of Research
Data/statistical analysis
Subject of Research
Human tissue samples
Article Title
Galectin-3 links microglial neuroinflammation to Aβ aggregation and lysosomal processing
Article Publication Date
18-Nov-2026